Jubilant Life Sciences’ arm initiates I-131 MIBG OPTIMUM Trials

23 Jul 2018 Evaluate

Jubilant Life Sciences’ wholly owned subsidiary -- Jubilant Pharma, through one of its units Jubilant DraxImage Inc. Montreal, Canada, has initiated OPTIMUM trial which is a Pivotal Phase II Clinical Trial designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma.

The study will include both male and female patients over the age of one year who show a return or persistence of this disease following initial therapy. Children enrolled in the OPTIMUM trial could receive up to two dose cycles of I-131 MIBG over a twenty-six week period.

The information collected from this study will be submitted to the United States Food and Drug Administration (USFDA) under the Orphan Drug Designation program and is eligible for accelerated approval if the clinical trials are successful. Jubilant’s MIBG has already been used for over a decade in USFDA approved expanded access trials and two Pediatric Oncology academic consortiums - NANT (New Approaches to Neuroblastoma Therapy) and COG (Children’s Oncology Group).

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

1046.65 -18.90 (-1.77%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×